Search

Your search keyword '"Bongiovanni D"' showing total 13 results
Start Over Author "Bongiovanni D" Publisher oxford university press (oup)
13 results on '"Bongiovanni D"'

7. Reticulated platelet mass cytometry reveals unexplored therapeutic targets in patients with chronic coronary syndrome

Author

Bongiovanni, D, primary, Klug, M, additional, Lazareva, O, additional, Kirmes, K, additional, Biasi, M, additional, Okrojek, R, additional, Gosetti, R, additional, Manz, Q, additional, Arend, L, additional, Bernett, J, additional, Von Scheidt, M, additional, Condorelli, G, additional, Laugwitz, K L, additional, List, M, additional, and Bernlochner, I, additional

Published
2021
Full Text
View/download PDF

9. Immature platelet fraction is a strong predictor of adverse cardiovascular events in patients with acute coronary syndrome. Results of the ISAR-REACT 5 reticulated platelet substudy

Author

Bongiovanni, D, primary, Mayer, K, additional, Schreiner, N, additional, Karschin, V, additional, Wustrow, I, additional, Gosetti, R, additional, Schunkert, H, additional, Laugwitz, K.L, additional, Schuepke, S, additional, Kastrati, A, additional, and Bernlochner, I, additional

Published
2020
Full Text
View/download PDF

10. ADP-induced platelet aggregation in patients with acute coronary syndrome treated with prasugrel or ticagrelor. Results of the ISAR REACT 5 platelet aggregation substudy

Author

Bongiovanni, D, primary, Mayer, K, additional, Schreiner, N, additional, Karschin, V, additional, Wustrow, I, additional, Gosetti, R, additional, Schuepke, S, additional, Schunkert, H, additional, Laugwitz, K.L, additional, Kastrati, A, additional, and Bernlochner, I, additional

Published
2020
Full Text
View/download PDF

11. 2181The prothrombotic transcriptome of reticulated platelets

Author

Bongiovanni, D, primary, Santamaria, G, additional, Klug, M, additional, Santovito, D, additional, Felicetta, A, additional, Hristov, M, additional, Aslani, M, additional, Weber, C, additional, Peano, C, additional, Condorelli, G, additional, Laugwitz, K L, additional, and Bernlochner, I, additional

Published
2019
Full Text
View/download PDF

13. Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis

Author

Valgimigli, Marco, Smits, Pieter C, Frigoli, Enrico, Bongiovanni, Dario, Tijssen, Jan, Hovasse, Thomas, Mafragi, Al, Ruifrok, Willem Theodoor, Karageorgiev, Dimitar, Aminian, Adel, Garducci, Stefano, Merkely, Bela, Routledge, Helen, Ando, Kenji, Diaz Fernandez, Josè Francisco, Cuisset, Thomas, Nesa Malik, Fazila Tun, Halabi, Majdi, Belle, Loic, Din, Jehangir, Beygui, Farzin, Abhyankar, Atul, Reczuch, Krzysztof, Pedrazzini, Giovanni, Heg, Dik, Vranckx, Pascal, MASTER DAPT Investigators, Cardiology, ACS - Heart failure & arrhythmias, Valgimigli, M, Smits, PC, Frigoli, E, Bongiovanni, D, Tijssen, J, Hovasse, T, Mafragi, A, Ruifrok, WT, Karageorgiev, D, Aminian, A, Garducci, S, Merkely, B, Routledge, H, Ando, K, Fernandez, JFD, Cuisset, T, Malik, FTN, Halabi, M, Belle, L, Din, J, Beygui, F, Abhyankar, A, Reczuch, K, Pedrazzini, G, Heg, D, and VRANCKX, Pascal

Subjects
animal structures, Aspirin, Myocardial Infarction, Hemorrhage, Percutaneous coronary intervention, Stroke, Treatment Outcome, Complex intervention, Dual antiplatelet therapy, Humans, Drug Therapy, Combination, Acute Coronary Syndrome, High bleeding risk, 610 Medizin und Gesundheit, Cardiology and Cardiovascular Medicine, Platelet Aggregation Inhibitors
Abstract

Aim To assess the effects of 1- or ≥3-month dual antiplatelet therapy (DAPT) in high bleeding risk (HBR) patients who received biodegradable-polymer sirolimus-eluting stents for complex percutaneous coronary intervention (PCI) and/or acute coronary syndrome (ACS). Methods and results In the MASTER DAPT trial, 3383 patients underwent non-complex (abbreviated DAPT, n = 1707; standard DAPT, n = 1676) and 1196 complex (abbreviated DAPT, n = 588; standard DAPT, n = 608) PCI. Co-primary outcomes at 335 days were net adverse clinical events [NACE; composite of all-cause death, myocardial infarction, stroke, and bleeding academic research consortium (BARC) 3 or 5 bleeding events]; major adverse cardiac or cerebral events (MACCE; all-cause death, myocardial infarction, and stroke); and Types 2, 3, or 5 BARC bleeding. Net adverse clinical events and MACCE did not differ with abbreviated vs. standard DAPT among patients with complex [hazard ratio (HR): 1.03, 95% confidence interval (CI): 0.69–1.52, and HR: 1.24, 95% CI: 0.79–1.92, respectively] and non-complex PCI (HR: 0.90, 95% CI: 0.71–1.15, and HR: 0.91, 95% CI: 0.69–1.21; Pinteraction = 0.60 and 0.26, respectively). BARC 2, 3, or 5 was reduced with abbreviated DAPT in patients with and without complex PCI (HR: 0.64; 95% CI: 0.42–0.98, and HR: 0.70; 95% CI: 0.55–0.89; Pinteraction = 0.72). Among the 2816 patients with complex PCI and/or ACS, NACE and MACCE did not differ and BARC 2, 3, or 5 was lower with abbreviated DAPT. Conclusion In HBR patients free from recurrent ischaemic events at 1 month, DAPT discontinuation was associated with similar NACE and MACCE and lower bleeding rates compared with standard DAPT, regardless of PCI or patient complexity. Clinical Trial Registration This trial is registered with ClinicalTrials.gov, number NCT03023020, and is closed to new participants, with follow-up completed.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results